Pazopanib: A novel multitargeted tyrosine kinase inhibitor

被引：162

作者：

Sonpavde G. ^{[1
]}

Hutson T.E. ^{[1
]}

机构：

[1] Texas Oncology P.A., Baylor Sammons Cancer Center, Dallas, TX 75246

来源：

Current Oncology Reports | 2007年 / 9卷 / 2期

关键词：

Vascular Endothelial Growth Factor; Renal Cell Carcinoma; Sorafenib; Lapatinib; Synovial Sarcoma;

D O I：

10.1007/s11912-007-0007-2

中图分类号：

学科分类号：

摘要：

Pazopanib (GW786034) is a second-generation multitargeted tyrosine kinase inhibitor against vascular endothelial growth factor receptor-1, -2, and -3, platelet-derived growth factor receptor-α, platelet-derived growth factor receptor-β and c-kit. Preclinical evaluation has revealed excellent antiangiogenic and antitumor activity, and synergism was observed in combination with chemotherapeutic drugs. Significant antitumor activity was found in animal models of a variety of tumors, accompanied by desirable pharmacokinetics and oral bioavailability. Phase I clinical trials have revealed manageable toxicities and desirable pharmacokinetics as well as activity in renal cancer and several other tumors. Ongoing trials are further evaluating pazopanib in a variety of malignancies. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：115 / 119

页数：4

共 25 条

[1]

Ullrich A., Schlessinger J., Signal transduction by receptors with tyrosine kinase activity, Cell, 61, pp. 203-212, (1990)

[2]

Hubbard S.R., Till J.H., Protein tyrosine kinases: Structure and function, Annu Rev Biochem, 69, pp. 373-398, (2000)

[3]

Yancopoulos G.D., Davis S., Gale N.W., Et al., Vascular-specific growth factors and blood vessel formation, Nature, 407, pp. 242-248, (2000)

[4]

Bilodeau M.T., Fraley M.E., Hartman G.D., Kinase insert domain-containing receptor kinase inhibitors as antiangiogenic agents, Expert Opin Invest Drugs, 11, (2002)

[5]

Holmgren L., O'Reilly M.S., Folkman J., Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression, Nat Med, 1, pp. 149-153, (1995)

[6]

Zetter B.R., Angiogenesis and tumor metastasis, Annu Rev Med, 49, pp. 407-424, (1998)

[7]

Lindahl P., Johansson B.R., Leveen P., Betsholtz C., Pericyte loss and microaneurysm formation in PDGF-B-deficient mice, Science, 277, pp. 242-245, (1997)

[8]

Demetri G.D., Targeting c-Kit mutations in solid tumors: Scientific rationale and novel therapeutic, Options Semin Oncol, 28, pp. 19-26, (2001)

[9]

Gschwind A., Fischer O.M., Ullrich A., The discovery of receptor tyrosine kinases: Targets for cancer therapy, Nat Rev, 4, pp. 361-370, (2004)

[10]

Dancey J., Sausville E.A., Issues and progress with protein kinase inhibitors for cancer treatment, Nat Rev Drug Discov, 2, pp. 296-313, (2003)

← 1 2 3 →